A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Trial Profile

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MK-3475-522/KEYNOTE-522
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 16 Mar 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Nov 2018.
    • 16 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top